Meeting
2023 ASCO Annual Meeting
A phase III randomized trial of neo-adjuvant chemotherapy in high-risk soft tissue sarcoma (ISG-STS 1001): Feasibility and activity of concurrent chemotherapy and radiation therapy.
Presenter
Elena Palassini, MD
Fondazione IRCCS Istituto Nazionale dei Tumori
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 11506)
DOI
10.1200/JCO.2023.41.16_suppl.11506
Abstract #
11506
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2012 ASCO Annual Meeting
Early response to neoadjuvant chemotherapy (NAC) in combination with regional hyperthermia (RHT) to predict long-term survival for adult-type high-risk soft tissue sarcoma (HR-STS): Results of the EORTC-ESHO intergroup phase III study.
Speaker: Rolf D. Issels, MD, PhD
Videos & Slides
2024 ASCO Annual Meeting
A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy.
Speaker: Pier Franco Conte, MD
Videos & Slides
2023 ASCO Annual Meeting
Histopathological response (HR) after neoadjuvant chemotherapy (ChT) for high-risk soft tissue sarcomas (STS): A planned analysis of the ISG-STS-1001 trial.
Speaker: Sandro Pasquali, MD, PhD
Videos & Slides
2022 ASCO Annual Meeting
Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: Results of the expanded cohort of myxoid liposarcoma of the randomized clinical trial from the Italian Sarcoma Group (ISG), the Spanish Sarcoma Group (GEIS), the French Sarcoma Group (FSG), and the Polish Sarcoma Group (PSG).
Speaker: Alessandro Gronchi, MD